BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stebbing J, Sánchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, Sommerauer C, Tiseo G, Ghiadoni L, Virdis A, Monzani F, Rizos LR, Forfori F, Avendaño Céspedes A, De Marco S, Carrozzi L, Lena F, Sánchez-Jurado PM, Lacerenza LG, Cesira N, Caldevilla Bernardo D, Perrella A, Niccoli L, Méndez LS, Matarrese D, Goletti D, Tan YJ, Monteil V, Dranitsaris G, Cantini F, Farcomeni A, Dutta S, Burley SK, Zhang H, Pistello M, Li W, Romero MM, Andrés Pretel F, Simón-Talero RS, García-Molina R, Kutter C, Felce JH, Nizami ZF, Miklosi AG, Penninger JM, Menichetti F, Mirazimi A, Abizanda P, Lauschke VM. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv 2021;7:eabe4724. [PMID: 33187978 DOI: 10.1126/sciadv.abe4724] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 47.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang C, Lee Y, Hsu H, Zhao G, Lee S. Tyrphostin AG1024 Suppresses Coronaviral Replication by Downregulating JAK1 via an IR/IGF-1R Independent Proteolysis Mediated by Ndfip1/2_NEDD4-like E3 Ligase Itch. Pharmaceuticals 2022;15:241. [DOI: 10.3390/ph15020241] [Reference Citation Analysis]
2 Assadiasl S, Fatahi Y, Mosharmovahed B, Mohebbi B, Nicknam MH. Baricitinib: From Rheumatoid Arthritis to COVID-19. J Clin Pharmacol 2021;61:1274-85. [PMID: 33870531 DOI: 10.1002/jcph.1874] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Cusinato J, Cau Y, Calvani AM, Mori M. Repurposing drugs for the management of COVID-19. Expert Opin Ther Pat 2021;31:295-307. [PMID: 33283567 DOI: 10.1080/13543776.2021.1861248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
4 Gajjela BK, Zhou MM. Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling. Drug Discov Today 2021:S1359-6446(21)00454-2. [PMID: 34743903 DOI: 10.1016/j.drudis.2021.10.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Panahi Y, Dadkhah M, Talei S, Gharari Z, Asghariazar V, Abdolmaleki A, Matin S, Molaei S. Can anti-parasitic drugs help control COVID-19? Future Virol 2022. [PMID: 35359702 DOI: 10.2217/fvl-2021-0160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kalyanaraman B. Reactive oxygen species, proinflammatory and immunosuppressive mediators induced in COVID-19: overlapping biology with cancer. RSC Chem Biol 2021;2:1402-14. [PMID: 34704045 DOI: 10.1039/d1cb00042j] [Reference Citation Analysis]
7 Li Y, Zhao W, Liu J, Chen Z, Lv Q, Zhang Z. Immunotherapy Summary for Cytokine Storm in COVID-19. Front Pharmacol 2021;12:731847. [PMID: 34603047 DOI: 10.3389/fphar.2021.731847] [Reference Citation Analysis]
8 Kishimoto T. Interleukin-6: From arthritis to CAR-T cell therapy and COVID-19. Int Immunol 2021:dxab011. [PMID: 33715009 DOI: 10.1093/intimm/dxab011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ho WS, Zhang R, Tan YL, Chai CLL. COVID-19 and The Promise of Small Molecule Therapeutics: Are There Lessons to be Learnt? Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
10 Youhanna S, Wright SC, Lauschke VM. Organotypic human ex vivo models for coronavirus disease 2019 research and drug development. Curr Opin Pharmacol 2021;59:11-8. [PMID: 34029832 DOI: 10.1016/j.coph.2021.04.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Najafi Fard S, Petrone L, Petruccioli E, Alonzi T, Matusali G, Colavita F, Castilletti C, Capobianchi MR, Goletti D. In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. Biomed Res Int 2021;2021:8856018. [PMID: 34239932 DOI: 10.1155/2021/8856018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Ezeonwumelu IJ, Garcia-Vidal E, Ballana E. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections. Viruses 2021;13:2379. [PMID: 34960648 DOI: 10.3390/v13122379] [Reference Citation Analysis]
13 Goletti D, Cantini F. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled. N Engl J Med 2021;384:867-9. [PMID: 33657299 DOI: 10.1056/NEJMe2034982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
14 Tang XD, Ji TT, Dong JR, Feng H, Chen FQ, Chen X, Zhao HY, Chen DK, Ma WT. Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. Int J Mol Sci 2021;22:13009. [PMID: 34884813 DOI: 10.3390/ijms222313009] [Reference Citation Analysis]
15 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
16 Zhou Y, Xu J, Hou Y, Leverenz JB, Kallianpur A, Mehra R, Liu Y, Yu H, Pieper AA, Jehi L, Cheng F. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. bioRxiv 2021:2021. [PMID: 33791705 DOI: 10.1101/2021.03.15.435423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Raghuvanshi R, Bharate SB. Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections. J Med Chem 2021. [PMID: 33539089 DOI: 10.1021/acs.jmedchem.0c01467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Huang J, Zhou C, Deng J, Zhou J. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Biochem Pharmacol 2022;:115162. [PMID: 35787993 DOI: 10.1016/j.bcp.2022.115162] [Reference Citation Analysis]
19 Schein CH. Repurposing approved drugs for cancer therapy. Br Med Bull 2021;137:13-27. [PMID: 33517358 DOI: 10.1093/bmb/ldaa045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Malik P, Jain S, Jain P, Kumawat J, Dwivedi J, Kishore D. A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2. Arch Pharm (Weinheim) 2022;:e2100382. [PMID: 35040187 DOI: 10.1002/ardp.202100382] [Reference Citation Analysis]
21 Gomaa AA, Mohamed HS, Abd-Ellatief RB, Gomaa MA. Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly. Inflammopharmacology 2021;29:1033-48. [PMID: 34224069 DOI: 10.1007/s10787-021-00841-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Thoms BL, Gosselin J, Libman B, Littenberg B, Budd R. Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19. Res Sq 2021:rs. [PMID: 34518834 DOI: 10.21203/rs.3.rs-835734/v1] [Reference Citation Analysis]
23 Buszko M, Nita-Lazar A, Park JH, Schwartzberg PL, Verthelyi D, Young HA, Rosenberg AS. Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol 2021;22:404-11. [PMID: 33723418 DOI: 10.1038/s41590-021-00901-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
24 Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel) 2021;14:738. [PMID: 34451835 DOI: 10.3390/ph14080738] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
25 Wallis RS, O’garra A, Sher A, Wack A. Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nat Rev Immunol. [DOI: 10.1038/s41577-022-00734-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Drosos AA, Pelechas E, Voulgari PV. Treatment strategies of Covid-19. A rheumatology perspective. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.014] [Reference Citation Analysis]
27 Ramasamy S, Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clin Microbiol Rev 2021;34:e00299-20. [PMID: 33980688 DOI: 10.1128/CMR.00299-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
28 White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ, Prasad VR. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 2021;12:e03347-21. [DOI: 10.1128/mbio.03347-21] [Reference Citation Analysis]
29 Selvaraj V, Finn A, Lal A, Khan MS, Dapaah-Afriyie K, Carino GP. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine 2022;49:101489. [PMID: 35677732 DOI: 10.1016/j.eclinm.2022.101489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Gopcsa L, Bobek I, Bekő G, Lakatos B, Molnár E, Réti M, Reményi P, Sinkó J, Szlávik J, Tatai G, Vályi-Nagy I. Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome. Acta Microbiol Immunol Hung 2021. [PMID: 34797216 DOI: 10.1556/030.2021.01620] [Reference Citation Analysis]
31 Xu J, Xiao W, Liang X, Shi L, Zhang P, Wang Y, Wang Y, Yang H. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health 2021;21:1533. [PMID: 34380456 DOI: 10.1186/s12889-021-11051-w] [Reference Citation Analysis]
32 Stebbing J, Lauschke VM. JAK Inhibitors - More Than Just Glucocorticoids. N Engl J Med 2021;385:463-5. [PMID: 34320294 DOI: 10.1056/NEJMe2108667] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Levy G, Guglielmelli P, Langmuir P, Constantinescu S. JAK inhibitors and COVID-19. J Immunother Cancer 2022;10:e002838. [PMID: 35459733 DOI: 10.1136/jitc-2021-002838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Beeraka NM, Tulimilli SV, Karnik M, Sadhu SP, Pragada RR, Aliev G, Madhunapantula SV. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). Biomed Res Int 2021;2021:8160860. [PMID: 34159203 DOI: 10.1155/2021/8160860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Youhanna S, Kemas AM, Preiss L, Zhou Y, Shen JX, Cakal SD, Paqualini FS, Goparaju SK, Shafagh RZ, Lind JU, Sellgren CM, Lauschke VM. Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives. Pharmacol Rev 2022;74:141-206. [PMID: 35017176 DOI: 10.1124/pharmrev.120.000238] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zizzo G, Tamburello A, Castelnovo L, Laria A, Mumoli N, Faggioli PM, Stefani I, Mazzone A. Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling. Front Immunol 2022;13:795315. [PMID: 35340805 DOI: 10.3389/fimmu.2022.795315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Ismail AA. SARS-CoV-2 (Covid-19): A short update on molecular biochemistry, pathology, diagnosis and therapeutic strategies. Ann Clin Biochem 2021;:4563221992390. [PMID: 33478237 DOI: 10.1177/0004563221992390] [Reference Citation Analysis]
38 Santoso CS, Li Z, Rottenberg JT, Liu X, Shen VX, Fuxman Bass JI. Therapeutic Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19. Front Pharmacol 2021;12:673485. [PMID: 34163359 DOI: 10.3389/fphar.2021.673485] [Reference Citation Analysis]
39 Wang ZN, Yang XS, Sun J, Zhao JC, Zhong NS, Tang XX. Multi-omics evaluation of SARS-CoV-2 infected mouse lungs reveals dynamics of host responses. iScience 2022;25:103967. [PMID: 35224468 DOI: 10.1016/j.isci.2022.103967] [Reference Citation Analysis]
40 Melikhov O, Kruglova T, Lytkina K, Melkonyan G, Prokhorovich E, Putsman G, Rodoman G, Vertkin A, Zagrebneva A, Stebbing J. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. Ann Rheum Dis 2021;80:1245-6. [PMID: 34099486 DOI: 10.1136/annrheumdis-2021-220049] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Tziolos N, Karofylakis E, Grigoropoulos I, Kazakou P, Koullias E, Savva A, Kranidioti H, Pelekanou A, Boulouta A, Pirounaki M, Tsiodras S, Georgiopoulos G, Boumpas DT, Kavatha D, Thomas K, Vassilopoulos D, Antoniadou A. Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. Open Forum Infect Dis 2022;9:ofab588. [PMID: 34988257 DOI: 10.1093/ofid/ofab588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Mengozzi A, Georgiopoulos G, Falcone M, Tiseo G, Pugliese NR, Dimopoulos MA, Ghiadoni L, Barbieri G, Forfori F, Carrozzi L, Santini M, Monzani F, De Marco S, Menichetti F, Virdis A, Masi S; Pisa Covid Study Group. The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome. Sci Rep 2021;11:6515. [PMID: 33753759 DOI: 10.1038/s41598-021-85646-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Pum A, Ennemoser M, Adage T, Kungl AJ. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. Biomolecules 2021;11:91. [PMID: 33445810 DOI: 10.3390/biom11010091] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
44 Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC, Alatorre-alexander J, Altclas JD, Casas M, Cevolirecio V, Ellerin T, Giovanni Luz K, Goldman JD, Juliani Souza Lima MP, Khan A, Paulin P, Procopio Carvalho AC, Rojas Velasco G, Saraiva JFK, Shawa I, Simon Campos J, Tiffany B, Westheimer Cavalcante A. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. The Lancet Respiratory Medicine 2022;10:327-36. [DOI: 10.1016/s2213-2600(22)00006-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
45 Lin Z, Niu J, Xu Y, Qin L, Ding J, Zhou L. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis. J Med Virol 2021. [PMID: 34846766 DOI: 10.1002/jmv.27482] [Reference Citation Analysis]
46 Hansen S, Alduaij W, Biggs CM, Belga S, Luecke K, Merkeley H, Chen LYC. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series. Eur J Haematol 2021;106:654-61. [PMID: 33523540 DOI: 10.1111/ejh.13593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 Gracia Villacampa E, Larsson L, Mirzazadeh R, Kvastad L, Andersson A, Mollbrink A, Kokaraki G, Monteil V, Schultz N, Appelberg KS, Montserrat N, Zhang H, Penninger JM, Miesbach W, Mirazimi A, Carlson J, Lundeberg J. Genome-wide spatial expression profiling in formalin-fixed tissues. Cell Genomics 2021;1:100065. [DOI: 10.1016/j.xgen.2021.100065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
48 Musiu C, Caligola S, Fiore A, Lamolinara A, Frusteri C, Del Pizzo FD, De Sanctis F, Canè S, Adamo A, Hofer F, Barouni RM, Grilli A, Zilio S, Serafini P, Tacconelli E, Donadello K, Gottin L, Polati E, Girelli D, Polidoro I, Iezzi PA, Angelucci D, Capece A, Chen Y, Shi ZL, Murray PJ, Chilosi M, Amit I, Bicciato S, Iezzi M, Bronte V, Ugel S. Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. Cell Death Differ 2021. [PMID: 34518653 DOI: 10.1038/s41418-021-00866-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia 2021;35:2616-20. [PMID: 33990684 DOI: 10.1038/s41375-021-01266-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
50 McConnell MJ, Kondo R, Kawaguchi N, Iwakiri Y. Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatol Commun 2021. [PMID: 34658172 DOI: 10.1002/hep4.1843] [Reference Citation Analysis]
51 Wanner N, Andrieux G, Badia-I-Mompel P, Edler C, Pfefferle S, Lindenmeyer MT, Schmidt-Lauber C, Czogalla J, Wong MN, Okabayashi Y, Braun F, Lütgehetmann M, Meister E, Lu S, Noriega MLM, Günther T, Grundhoff A, Fischer N, Bräuninger H, Lindner D, Westermann D, Haas F, Roedl K, Kluge S, Addo MM, Huber S, Lohse AW, Reiser J, Ondruschka B, Sperhake JP, Saez-Rodriguez J, Boerries M, Hayek SS, Aepfelbacher M, Scaturro P, Puelles VG, Huber TB. Molecular consequences of SARS-CoV-2 liver tropism. Nat Metab 2022. [PMID: 35347318 DOI: 10.1038/s42255-022-00552-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
52 Hsu J, Liu CH, Wei JC. Suggested Considerations for the Treatment of Rheumatic Diseases in Adult Patients With COVID-19: Comment on the Article by Mikuls et al. Arthritis Rheumatol 2021;73:2355. [PMID: 34105903 DOI: 10.1002/art.41889] [Reference Citation Analysis]
53 Stamatelopoulos K, Georgiopoulos G, Baker KF, Tiseo G, Delialis D, Lazaridis C, Barbieri G, Masi S, Vlachogiannis NI, Sopova K, Mengozzi A, Ghiadoni L, van der Loeff IS, Hanrath AT, Ajdini B, Vlachopoulos C, Dimopoulos MA, Duncan CJA, Falcone M, Stellos K; Pisa COVID-19 Research Group., Newcastle COVID-19 Research Group. Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19. Sci Rep 2021;11:20239. [PMID: 34642385 DOI: 10.1038/s41598-021-99050-0] [Reference Citation Analysis]
54 Santoso CS, Li Z, Rottenberg JT, Liu X, Shen VX, Bass JIF. In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19. bioRxiv 2020:2020. [PMID: 33398281 DOI: 10.1101/2020.12.29.424728] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Smet A, Breugelmans T, Michiels J, Lamote K, Arras W, De Man JG, Heyndrickx L, Hauner A, Huizing M, Malhotra-Kumar S, Lammens M, Hotterbeekx A, Kumar-Singh S, Verstraeten A, Loeys B, Verhoeven V, Jacobs R, Dams K, Coenen S, Ariën KK, Jorens PG, De Winter BY. A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity. JCI Insight 2021;6:e151777. [PMID: 34448730 DOI: 10.1172/jci.insight.151777] [Reference Citation Analysis]
56 Tiseo G, Yahav D, Paul M, Tinelli M, Gavazzi G, Mussini C, Prendki V, Falcone M. What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. Eur J Clin Microbiol Infect Dis 2021. [PMID: 34775534 DOI: 10.1007/s10096-021-04377-1] [Reference Citation Analysis]
57 Qu C, Fuhler GM, Pan Y. Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19? Int J Mol Sci 2021;22:5672. [PMID: 34073529 DOI: 10.3390/ijms22115672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Senderovich H, Vinoraj D, Stever M, Waicus S. Efficacy of COVID-19 treatments among geriatric patients: a systematic review. Therapeutic Advances in Infection 2022;9:204993612210956. [DOI: 10.1177/20499361221095666] [Reference Citation Analysis]
59 Romei C, Falaschi Z, Danna PSC, Airoldi C, Tonerini M, Rocchi E, Fanni SC, D'Amelio C, Barbieri G, Tiseo G, Arioli R, Paschè A, Karwoski RA, De Liperi A, Bartholmai BJ, Carriero A. Lung vessel volume evaluated with CALIPER software is an independent predictor of mortality in COVID-19 patients: a multicentric retrospective analysis. Eur Radiol 2022. [PMID: 35028751 DOI: 10.1007/s00330-021-08485-6] [Reference Citation Analysis]
60 Carbone M, Lednicky J, Xiao SY, Venditti M, Bucci E. Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. J Thorac Oncol 2021;16:546-71. [PMID: 33422679 DOI: 10.1016/j.jtho.2020.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
61 Mohamed FF, Anhlan D, Schöfbänker M, Schreiber A, Classen N, Hensel A, Hempel G, Scholz W, Kühn J, Hrincius ER, Ludwig S. Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2. Pharmaceuticals 2022;15:530. [DOI: 10.3390/ph15050530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Giri A, Srinivasan A, Sundar IK. COVID-19: Sleep, Circadian Rhythms and Immunity - Repurposing Drugs and Chronotherapeutics for SARS-CoV-2. Front Neurosci 2021;15:674204. [PMID: 34220430 DOI: 10.3389/fnins.2021.674204] [Reference Citation Analysis]
63 Richardson PJ, Robinson BWS, Smith DP, Stebbing J. The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. Vaccines (Basel) 2022;10:951. [PMID: 35746559 DOI: 10.3390/vaccines10060951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Vallianou NG, Tsilingiris D, Christodoulatos GS, Karampela I, Dalamaga M. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. Metabol Open 2021;10:100096. [PMID: 34056571 DOI: 10.1016/j.metop.2021.100096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Alfaro-Martínez JJ, Solís García Del Pozo J, Lamas Oliveira C, Paterna Mellinas G, García-Castillo S, Molina Cifuentes M, Pinés Corrales P. Hospital capacity and admission rate may be a factor of importance to mortality in COVID-19. Infect Dis (Lond) 2021;:1-3. [PMID: 34751087 DOI: 10.1080/23744235.2021.2001565] [Reference Citation Analysis]
66 Wong CKH, Lau KTK, Au ICH, Xiong X, Chung MSH, Leung BYC, Lau EHY, Cowling BJ. Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone. Front Pharmacol 2022;13:866441. [DOI: 10.3389/fphar.2022.866441] [Reference Citation Analysis]
67 Ravid JD, Leiva O, Chitalia VC. Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations. Cells 2022;11:306. [DOI: 10.3390/cells11020306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Putlyaeva LV, Lukyanov KA. Studying SARS-CoV-2 with Fluorescence Microscopy. Int J Mol Sci 2021;22:6558. [PMID: 34207305 DOI: 10.3390/ijms22126558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Mak KK, Balijepalli MK, Pichika MR. Success stories of AI in drug discovery - where do things stand? Expert Opin Drug Discov 2021;:1-14. [PMID: 34553659 DOI: 10.1080/17460441.2022.1985108] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Leigh KE, Modis Y. Imaging and visualizing SARS-CoV-2 in a new era for structural biology. Interface Focus 2021;11:20210019. [PMID: 34956593 DOI: 10.1098/rsfs.2021.0019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Lobo CS, Rodrigues-Santos P, Pereira D, Núñez J, Trêpa JCD, Sousa DL, Lourenço JV, Coelho MF, de Almeida LP, da Cunha JS, Arnaut LG. Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation. Photochem Photobiol Sci 2022. [PMID: 35304729 DOI: 10.1007/s43630-022-00202-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Singh N, Villoutreix BO. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Comput Struct Biotechnol J 2021;19:2537-48. [PMID: 33936562 DOI: 10.1016/j.csbj.2021.04.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, Kolundzic N, Abdulle AE, van der Voort PH, Olde Rikkert MG, van der Hoeven JG, den Dunnen WF, Hillebrands JL, van Goor H. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J Pathol 2021;254:307-31. [PMID: 33586189 DOI: 10.1002/path.5642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
74 Alexander M, Luo Y, Raimondi G, O'Shea JJ, Gadina M. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies. Pharmaceuticals (Basel) 2021;15:48. [PMID: 35056105 DOI: 10.3390/ph15010048] [Reference Citation Analysis]
75 Saber-Ayad M, Hammoudeh S, Abu-Gharbieh E, Hamoudi R, Tarazi H, Al-Tel TH, Hamid Q. Current Status of Baricitinib as a Repurposed Therapy for COVID-19. Pharmaceuticals (Basel) 2021;14:680. [PMID: 34358107 DOI: 10.3390/ph14070680] [Reference Citation Analysis]
76 Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021:S2213-2600(21)00331-3. [PMID: 34480861 DOI: 10.1016/S2213-2600(21)00331-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 13.0] [Reference Citation Analysis]
77 Ingelman-Sundberg M, Lauschke VM. 3D human liver spheroids for translational pharmacology and toxicology. Basic Clin Pharmacol Toxicol 2021. [PMID: 33872466 DOI: 10.1111/bcpt.13587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Zhang X, Shang L, Fan G, Gu X, Xu J, Wang Y, Huang L, Cao B. The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:800492. [PMID: 35155477 DOI: 10.3389/fmed.2021.800492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Limen RY, Sedono R, Sugiarto A, Hariyanto TI. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther 2021;:1-10. [PMID: 34538216 DOI: 10.1080/14787210.2021.1982695] [Reference Citation Analysis]
80 Brüssow H. Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. Environ Microbiol 2021. [PMID: 34729893 DOI: 10.1111/1462-2920.15828] [Reference Citation Analysis]
81 Biddle K, White JPE, Sofat N. What is the full potential of baricitinib in treating patients with COVID-19? Expert Rev Clin Immunol 2022. [PMID: 35486502 DOI: 10.1080/1744666X.2022.2072298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Bittremieux W, Adams C, Laukens K, Dorrestein PC, Bandeira N. Open Science Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2. J Proteome Res 2021;20:1464-75. [PMID: 33605735 DOI: 10.1021/acs.jproteome.0c00929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Pérez-Alba E, Nuzzolo-Shihadeh L, Aguirre-García GM, Espinosa-Mora J, Lecona-Garcia JD, Flores-Pérez RO, Mendoza-Garza M, Camacho-Ortiz A. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. J Microbiol Immunol Infect 2021:S1684-1182(21)00133-X. [PMID: 34294593 DOI: 10.1016/j.jmii.2021.05.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Vologzhanin DA, Golota AS, Kamilova TA, Shneider OV, Sherbak SG. Genetics of COVID-19. Journal of Clinical Practice 2021;12:41-52. [DOI: 10.17816/clinpract64972] [Reference Citation Analysis]
85 Spinelli FR, Meylan F, O'Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol 2021;51:1615-27. [PMID: 33930196 DOI: 10.1002/eji.202048922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Zhou Y, Xu J, Hou Y, Leverenz JB, Kallianpur A, Mehra R, Liu Y, Yu H, Pieper AA, Jehi L, Cheng F. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimers Res Ther 2021;13:110. [PMID: 34108016 DOI: 10.1186/s13195-021-00850-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
87 Čikoš A, Dragojević S, Kubiček A. Degradation products of azetidine core G334089 - Isolation, structure elucidation and pathway. J Pharm Biomed Anal 2021;203:114232. [PMID: 34246845 DOI: 10.1016/j.jpba.2021.114232] [Reference Citation Analysis]
88 Smith DP, Oechsle O, Rawling MJ, Savory E, Lacoste AMB, Richardson PJ. Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19. Front Pharmacol 2021;12:709856. [PMID: 34393789 DOI: 10.3389/fphar.2021.709856] [Reference Citation Analysis]